Oramed Pharmaceuticals Inc. — Director's Dealing 2012

Nov 6, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2012-11-02

Reporting Person: REGALS CAPITAL MANAGEMENT LP (10% Owner)
Reporting Person: Regals Fund LP (10% Owner)
Reporting Person: Slager David Mark (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-02	Common Stock	P	405405	—	Acquired	9127670	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-02	Warrants (Right to Purchase)	$.5	P	202703	Acquired	2017-11-02	Common Stock (202703)	Indirect

Footnotes

F1: On November 2, 2012, the Fund purchased units representing 405,405 shares of common stock and the 202,703 warrants described in this Form 4 for $0.37 per unit.

F2: Regals Capital Management LP, a Delaware limited partnership ("Regals Management"), Regals Fund LP, a Delaware limited partnership (the "Fund"), and David M. Slager ("Mr. Slager"), are the reporting persons (the "Reporting Persons") for the referenced securities. Mr. Slager is Managing Member of the general partner of Regals Management. Regals Management is the investment manager of the Fund. The shares of the issuer's common stock reported herein are held for the account of the Fund.

F3: As a result, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Fund for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended (the "Act"). Pursuant to Rule 16a-1(a)(4) under the Act, Regals Management and Mr. Slager disclaim beneficial ownership in the securities owned by the Fund except to the extent, if any, of their pecuniary interest therein.